Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.
Saved in:
| Title: | Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study. |
|---|---|
| Authors: | Verbeek MWC; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Rodríguez BS; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Sedek L; Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland.; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Laqua A; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Buracchi C; Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy., Buysse M; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic., Oliveira E; Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Morf D; Institute for Laboratory Medicine, Aarau, Switzerland., Oude Alink SR; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Barrena S; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Kohlscheen S; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Nierkens S; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hofmans M; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Fernandez P; Institute for Laboratory Medicine, Aarau, Switzerland., de Costa ES; Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Mejstrikova E; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic., Szczepanski T; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Slota L; Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland., Brüggemann M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Gaipa G; Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy., Grigore G; Cytognos SL, Salamanca, Spain., van Dongen JJM; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Immunology, Leiden University Medical Center (LUMC), The Netherlands., Orfao A; Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., van der Velden VHJ; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. |
| Source: | Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 Jul; Vol. 106 (4), pp. 252-263. Date of Electronic Publication: 2023 Sep 22. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 101235690 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4957 (Electronic) Linking ISSN: 15524949 NLM ISO Abbreviation: Cytometry B Clin Cytom Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-4957 |
|---|---|
| DOI: | 10.1002/cyto.b.22143 |
